This Phase III trial investigated whether the recMAGEA + AS15 cancer immunotherapeutic (MAGE-A3 CI) as adjuvant therapy improved DFS in patients with resected NSCLC. Here, MAGEA3 is linked to non-small cell lung carcinoma.